Literature DB >> 24678407

Spinal cord pathology in chronic experimental Toxoplasma gondii infection.

L Möhle, A Parlog, J Pahnke, I R Dunay.   

Abstract

Infection with the protozoan Toxoplasma (T.) gondii causes chronic infection of the central nervous system and can lead to life-threatening encephalomyelitis in immunocompromised patients. While infection with T. gondii has long time been considered asymptomatic in immunocompetent hosts, this view is challenged by recent reports describing links between seropositivity and behavioral alterations. However, past and current researches are mainly focused on the brain during Toxoplasma encephalitis, neglecting the spinal cord as a key structure conveying brain signals into motion. Therefore, our study aimed to fill the gap and describes the spinal cord pathology in an experimental murine model of toxoplasmosis. In the spinal cord, we found distinct histopathological changes, inflammatory foci and T. gondii cysts similar to the brain. Furthermore, the recruitment of immune cells from the periphery was detected. Moreover, resident microglia as well as recruited monocytes displayed an increased MHC classes I and II expression. Additionally, the expression of pro- and anti-inflammatory cytokines was enhanced in the brain as well as in the spinal cord. In summary, the pathology observed in the spinal cord was similar to the previously described changes in the brain during the infection. This study provides the first detailed description of histopathological and immunological alterations due to experimental T. gondii induced myelitis in mice. Thus, our comparison raises awareness of the importance of the spinal cord in chronic T. gondii infection.

Entities:  

Keywords:  Toxoplasma gondii; infection; inflammation; myelitis; spinal cord

Year:  2014        PMID: 24678407      PMCID: PMC3955833          DOI: 10.1556/EuJMI.4.2014.1.6

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  67 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 2.  Anti-TNF therapy in the injured spinal cord.

Authors:  Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Trends Pharmacol Sci       Date:  2010-12-23       Impact factor: 14.819

3.  Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice.

Authors:  Markus Krohn; Cathleen Lange; Jacqueline Hofrichter; Katja Scheffler; Jan Stenzel; Johannes Steffen; Toni Schumacher; Thomas Brüning; Anne-Sophie Plath; Franziska Alfen; Anke Schmidt; Felix Winter; Katja Rateitschak; Andreas Wree; Jörg Gsponer; Lary C Walker; Jens Pahnke
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

4.  Effects of toxoplasma on human behavior.

Authors:  Jaroslav Flegr
Journal:  Schizophr Bull       Date:  2007-01-11       Impact factor: 9.306

5.  Decrease of psychomotor performance in subjects with latent 'asymptomatic' toxoplasmosis.

Authors:  J Havlícek; Z G Gasová; A P Smith; K Zvára; J Flegr
Journal:  Parasitology       Date:  2001-05       Impact factor: 3.234

6.  The inflammatory cytokine, interleukin-1 beta, mediates loss of astroglial glutamate transport and drives excitotoxic motor neuron injury in the spinal cord during acute viral encephalomyelitis.

Authors:  Natalie A Prow; David N Irani
Journal:  J Neurochem       Date:  2008-01-14       Impact factor: 5.372

7.  Behavioural abnormalities in Toxoplasma-infected mice.

Authors:  W M Hutchinson; M Bradley; W M Cheyne; B W Wells; J Hay
Journal:  Ann Trop Med Parasitol       Date:  1980-06

8.  Both lymphotoxin-alpha and TNF are crucial for control of Toxoplasma gondii in the central nervous system.

Authors:  Dirk Schlüter; Lai-Yu Kwok; Sonja Lütjen; Sabine Soltek; Sigrid Hoffmann; Heinrich Körner; Martina Deckert
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

9.  The neurotropic parasite Toxoplasma gondii increases dopamine metabolism.

Authors:  Emese Prandovszky; Elizabeth Gaskell; Heather Martin; J P Dubey; Joanne P Webster; Glenn A McConkey
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

10.  Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitis.

Authors:  Beena John; Brendon Ricart; Elia D Tait Wojno; Tajie H Harris; Louise M Randall; David A Christian; Beth Gregg; Daniel Manzoni De Almeida; Wolfgang Weninger; Daniel A Hammer; Christopher A Hunter
Journal:  PLoS Pathog       Date:  2011-09-15       Impact factor: 6.823

View more
  17 in total

1.  Spinal cord toxoplasmosis in a young immunocompetent patient.

Authors:  M Martinot; V Greigert; C Farnarier; M L Dardé; C Piperoglou; M Mohseni-Zadeh; J Tarabeux; A Guffroy; O Villard; F Vely
Journal:  Infection       Date:  2019-12-09       Impact factor: 3.553

2.  Toxoplasma gondii Infection Promotes Neuroinflammation Through Cytokine Networks and Induced Hyperalgesia in BALB/c Mice.

Authors:  Hossein Mahmoudvand; Naser Ziaali; Hamed Ghazvini; Saeideh Shojaee; Hossein Keshavarz; Khadijeh Esmaeilpour; Vahid Sheibani
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

3.  Specific depletion of Ly6C(hi) inflammatory monocytes prevents immunopathology in experimental cerebral malaria.

Authors:  Beatrix Schumak; Katrin Klocke; Janina M Kuepper; Aindrila Biswas; Andrea Djie-Maletz; Andreas Limmer; Nico van Rooijen; Matthias Mack; Achim Hoerauf; Ildiko Rita Dunay
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

4.  Nucleotide-oligomerization-domain-2 affects commensal gut microbiota composition and intracerebral immunopathology in acute Toxoplasma gondii induced murine ileitis.

Authors:  Markus M Heimesaat; Ildiko R Dunay; Marie Alutis; André Fischer; Luisa Möhle; Ulf B Göbel; Anja A Kühl; Stefan Bereswill
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

5.  Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes.

Authors:  Luisa Möhle; Nicole Israel; Kristin Paarmann; Markus Krohn; Sabine Pietkiewicz; Andreas Müller; Inna N Lavrik; Jeffrey S Buguliskis; Björn H Schott; Dirk Schlüter; Eckart D Gundelfinger; Dirk Montag; Ulrike Seifert; Jens Pahnke; Ildiko Rita Dunay
Journal:  Acta Neuropathol Commun       Date:  2016-03-16       Impact factor: 7.801

6.  Behavior of Neutrophil Granulocytes during Toxoplasma gondii Infection in the Central Nervous System.

Authors:  Aindrila Biswas; Timothy French; Henning P Düsedau; Nancy Mueller; Monika Riek-Burchardt; Anne Dudeck; Ute Bank; Thomas Schüler; Ildiko Rita Dunay
Journal:  Front Cell Infect Microbiol       Date:  2017-06-21       Impact factor: 5.293

7.  Longitudinally Extensive Transverse Myelitis Due to Toxoplasma: An Autopsy Study.

Authors:  Yareeda Sireesha; Megha S Uppin; Komal Bohra; Rajesh Alugolu; Mathukumalli L Neeharika; Angamuthu Kanikannan
Journal:  Ann Indian Acad Neurol       Date:  2018 Apr-Jun       Impact factor: 1.383

8.  The impact of Toll-like-receptor-9 on intestinal microbiota composition and extra-intestinal sequelae in experimental Toxoplasma gondii induced ileitis.

Authors:  Stefan Bereswill; Anja A Kühl; Ildikò R Dunay; Markus M Heimesaat; Marie Alutis; André Fischer; Luisa Möhle; Daniela Struck; Oliver Liesenfeld; Ulf B Göbel
Journal:  Gut Pathog       Date:  2014-06-06       Impact factor: 4.181

9.  Phosphatidylthreonine and Lipid-Mediated Control of Parasite Virulence.

Authors:  Ruben D Arroyo-Olarte; Jos F Brouwers; Arunakar Kuchipudi; J Bernd Helms; Aindrila Biswas; Ildiko R Dunay; Richard Lucius; Nishith Gupta
Journal:  PLoS Biol       Date:  2015-11-13       Impact factor: 8.029

10.  Peroral Low-Dose Toxoplasma gondii Infection of Human Microbiota-Associated Mice - A Subacute Ileitis Model to Unravel Pathogen-Host Interactions.

Authors:  Markus M Heimesaat; Ulrike Escher; Anne Grunau; Ulrike Fiebiger; Stefan Bereswill
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.